BetterLife Pharma forms psychedelic research advisory board and taps industry veteran Hattie Wells as its first member

BetterLife Pharma Inc (CSE:BETR) (OTCQB:BETRF) tapped the experience of psychedelic pioneer Hattie Wells to join its new psychedelic research advisory board.

The Vancouver-based firm is forming the Next Generation Psychedelic Research Advisory Board with Wells as its first member, according to a statement Thursday.

Wells brings over 20 years of experience in the psychedelics space, working with molecules and looking at the therapeutic benefits for mental health disorders. Her research appeared in the Multidisciplinary Association for Psychedelic Studies and she currently serves as co-director of Breaking Convention, Europe’s largest conference on psychedelic consciousness.